Sunesis Pharmaceuticals (SNSS) Short Interest Ratio & Short Volume

Short interest is the volume of Sunesis Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of February 12th, traders have sold 1,150,000 shares of SNSS short. 7.10% of Sunesis Pharmaceuticals' shares are currently sold short. Learn More on Sunesis Pharmaceuticals' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 7.10% of Sunesis Pharmaceuticals' floating shares are currently sold short.

Sunesis Pharmaceuticals saw a decline in short interest during the month of February. As of February 12th, there was short interest totaling 1,150,000 shares, a decline of 5.7% from the previous total of 1,220,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Sunesis Pharmaceuticals currently has issued a total of 18,093,000 shares. Some of Sunesis Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Sunesis Pharmaceuticals currently has a public float of 16,200,000 shares.

7.10% of Sunesis Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Sunesis Pharmaceuticals: Emergent BioSolutions Inc. (11.38%), Bolt Biotherapeutics, Inc. (8.20%), Fortress Biotech, Inc. (14.08%), Regulus Therapeutics Inc. (9.44%), Rigel Pharmaceuticals, Inc. (2.86%), Vanda Pharmaceuticals Inc. (4.57%), Verastem, Inc. (3.10%), XOMA Co. (2.36%), Seres Therapeutics, Inc. (12.45%), Oramed Pharmaceuticals Inc. (1.44%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Aon plc ($5.62 billion), Charter Communications, Inc. ($5.35 billion), Analog Devices, Inc. ($5.07 billion), Snap Inc. ($3.60 billion), Futu Holdings Limited ($2.92 billion), Palantir Technologies Inc. ($2.55 billion), Airbnb, Inc. ($2.52 billion), Snowflake Inc. ($2.38 billion), Peloton Interactive, Inc. ($2.22 billion), and The Kroger Co. ($2.07 billion). View all of the most shorted stocks.

Short selling SNSS is an investing strategy that aims to generate trading profit from Sunesis Pharmaceuticals as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Sunesis Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of SNSS, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SNSS, twice per month. The most recent reporting period available is February, 12 2021.